

Dorte Linnemann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7985401/publications.pdf>

Version: 2024-02-01

20
papers

421
citations

759055

12
h-index

839398

18
g-index

20
all docs

20
docs citations

20
times ranked

950
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. <i>British Journal of Cancer</i> , 2016, 114, 134-137.	2.9	73
2	Three years of colorectal cancer screening in Denmark. <i>Cancer Epidemiology</i> , 2018, 57, 39-44.	0.8	57
3	Validity of data in the Danish Colorectal Cancer Screening Database. <i>Clinical Epidemiology</i> , 2017, Volume 9, 105-111.	1.5	46
4	Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab. <i>PLoS ONE</i> , 2014, 9, e109430.	1.1	39
5	Clinical Implications of Intestinal Stem Cell Markers in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 63-71.	1.0	34
6	MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability. <i>BMC Cancer</i> , 2015, 15, 1024.	1.1	27
7	SOX9 expression predicts relapse of stage II colon cancer patients. <i>Human Pathology</i> , 2016, 52, 38-46.	1.1	24
8	Topoisomerase α 1 and α 2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers. <i>Molecular Oncology</i> , 2015, 9, 1207-1217.	2.1	23
9	Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 5655-5667.	3.2	21
10	Cellular inhibitor of apoptosis protein 2 controls human colonic epithelial restitution, migration, and Rac1 activation. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, G92-G99.	1.6	18
11	Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. <i>BMC Cancer</i> , 2017, 17, 48.	1.1	17
12	Seeding after ultrasound-guided percutaneous biopsy of liver metastases in patients with colorectal or breast cancer. <i>Acta Oncologica</i> , 2016, 55, 638-643.	0.8	16
13	ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5027.	1.8	7
14	Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue. <i>Scientific Reports</i> , 2016, 6, 26997.	1.6	6
15	The prognostic value of polycomb group protein B-cell-specific moloney murine leukemia virus insertion site 1 in stage II colon cancer patients. <i>Apmis</i> , 2016, 124, 541-546.	0.9	4
16	Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. <i>International Journal of Cancer</i> , 2021, 148, 2542-2556.	2.3	4
17	Exome sequencing of 22 genes using tissue from patients with biliary tract cancer. <i>Apmis</i> , 2020, 128, 3-9.	0.9	3
18	Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3572-3572.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Seeding after biopsy of liver metastases in patients with primary colorectal and breast cancer.. Journal of Clinical Oncology, 2014, 32, e14545-e14545.	0.8	0
20	Outcome of cetuximab plus irinotecan in relation to <i>RAS</i> and <i>BRAF</i> mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan.. Journal of Clinical Oncology, 2016, 34, e15115-e15115.	0.8	0